Pacific Biosciences Reports Q3 2026 Revenue Growth Amidst Platform Transitions
Pacific Biosciences (PACB) reported third-quarter revenue of $40.6 million, a 6% increase compared to the same period in 2025. The company's growth was supported by a 16% rise in instrument revenue, driven by Revio placements in EMEA and increased Vega shipments. However, gross margins fell to 36% from 42% last year due to higher memory costs and manufacturing transition expenses for the Vega platform. Despite steady consumables growth, the company faces headwinds in the Americas, where instrument revenue declined by 24% due to funding uncertainties in academic and NIH sectors. To improve profitability, PacBio has implemented restructuring initiatives that reduced operating expenses by 13% and lowered headcount. The company narrowed its full-year revenue guidance to $155 million–$160 million as it monitors global capital spending trends.
Topics: gross margin net loss product placements restructuring revenue growth